

**TEPMETKO
(tepotinib)**

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Metastatic non-small cell lung cancer (NSCLC)

AND ALL of the following:

- a. Plasma or tumor specimens show **ONE** of the following:
 - i. High-level mesenchymal-epithelial transition (MET) amplification
 - ii. MET exon 14 skipping alterations
- b. Prescriber agrees to monitor for new or worsening pulmonary symptoms indicative of interstitial lung disease (ILD)/pneumonitis
- c. Patient has had baseline liver function tests (LFTs) performed before starting Tepmetko and prescriber agrees to monitor LFTs
- d. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Tepmetko and for 1 week after the final dose
- e. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Tepmetko and for 1 week after the final dose

Prior - Approval Limits

Quantity 180 tablets per 90 days

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis



**BlueCross
BlueShield**

Federal Employee Program.

TEPMETKO (tepotinib)

Patient must have the following:

Metastatic non-small cell lung cancer (NSCLC)

AND ALL of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor for new or worsening pulmonary symptoms indicative of interstitial lung disease (ILD)/pneumonitis
- c. Prescriber agrees to monitor liver function tests (LFTs)
- d. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Tepmetko and for 1 week after the final dose
- e. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Tepmetko and for 1 week after the final dose

Prior - Approval *Renewal* Limits

Same as above